SUSAN M DIMICK

Allopathic & Osteopathic Physicians|Family Medicine EDMOND, OK NPI 1083663611

General Payments — all program years on this page

$41,704.00

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 161
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,335.15 across 11 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Medicure Pharma Inc. $1,622.342
Amgen Inc. $318.535
NOVARTIS PHARMACEUTICALS CORPORATION $164.272
Novo Nordisk AS $115.421
Regeneron Healthcare Solutions, Inc. $114.591

By program year

Program yearAmountRecords
2018 $14,254.5343
2019 $8,757.3035
2020 $8,559.0216
2021 $5,290.5120
2022 $1,108.8417
2023 $1,398.6519
2024 $2,335.1511

Records — PY2024 (11)

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.